Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPRFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $276,000.

A number of other institutional investors have also recently made changes to their positions in the business. Krilogy Financial LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $287,000. JPMorgan Chase & Co. increased its position in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after acquiring an additional 45,381 shares during the period. Virtu Financial LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at $458,000. Barclays PLC raised its stake in shares of Capricor Therapeutics by 106.6% in the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after acquiring an additional 18,724 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Capricor Therapeutics in the third quarter valued at $938,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 6.0 %

Shares of NASDAQ:CAPR opened at $14.90 on Thursday. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The company’s fifty day moving average price is $15.22 and its 200 day moving average price is $11.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CAPR shares. Piper Sandler began coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target on the stock. Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald increased their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.50.

View Our Latest Research Report on Capricor Therapeutics

Capricor Therapeutics Profile

(Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More

Institutional Ownership by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.